First Batch of High-Value Medical Consumables Undergoes Price Governance (With Product List)
Medtronic
Medical Device Manufacturer
Abbott
Provider of Health Diagnostic Products and Health Diagnostic Management Solutions
The pricing logic for medical consumables is being rewritten.
Results of the First Batch of Price Governance for High-Value Consumables Announced
(Attached List)
June 24,Inner MongoliaThe Pharmaceutical Procurement Center Issued a Notice Requiring Enterprises to Voluntarily Reduce the Listed Prices of Certain Consumables by June 30, with Suspension of Listing Eligibility for Overdue Compliance.The following day,Hunan ProvinceThe Public Resource Trading Center also issued an implementation notice, specifying that prices and statuses must be adjusted by 16:00 on June 30.
It is worth mentioning that, the policy documents issued by both provinces were based on those released by the Department of Pharmaceutical Price and Procurement Bidding of the National Healthcare Security Administration"Letter on the Announcement of the Results of the Centralized Governance of Prices for the First Batch of High-Value Medical Consumables"Therefore, it is estimated thatRecentProvinces will follow suit in succession.
As early asThis March, the industry has reportedStatus of Provincial Adoption for the First Batch of Price Governance Initiatives, Beijing-Tianjin-Hebei, Fujian, Sichuan, Guangdong, Zhejiang, Jiangsu, Gansu, Hunan, Shaanxi, Henan, and Tianjin each claimed one high-value consumable product category, withCategories Listed in the Initial Batch of Centralized Governance Reports on High-Value Medical Consumables Published by Inner Mongolia and HunanPerfect Match。
It is understood that the first batch of the list involves19 Categories of High-Value Consumables, totaling 509 products, of which 424 were required to undergo price adjustments,85 Suspended from Online Listing. In terms of manufacturers, involvingMedtronic, Abbott, Boston Scientific, Johnson & Johnson, Biotronik, MicroPort EP, Xinuopu, LifeTechWait74 Domestic and International Medical Device Companies.
Click the official account card below, and reply with the number “624”
View NowFirst Batch of High-Value Consumables Price Governance List
Comprehensive rollout of price governance,
The Pricing Logic for Medical Consumables Will Be Completely Rewritten
In May this year, the National Healthcare Security Administration held a meeting on price governance in Zhangzhou, addressingRed-Yellow-Green Warning Mechanismand verificationNon-Centralized Procurement ItemsDeployed the implementation of measures concerning the reasonableness of price differentials among cost price, ex-factory price, and online listing price.
Red, yellow, and green labels are anchored to the winning bid prices in centralized procurement:Green label: normal procurement, no pop-up; Yellow label: single pop-up reminder; Red label: multiple pop-up warnings.。For products included in the centralized volume-based procurement (VBP), the highest selected bid price serves as the anchor; for non-VBP products, the ex-factory price serves as the anchor. Price differential reasonableness is verified across three tiers. Certain products may also have a "high threshold"; even if the price differential falls within the acceptable range, exceeding 1.8 times this high threshold may result in a yellow or red flag.
Cost verification is more fundamental. In the past, enterprises mainly relied on self-declaration to determine their quoted prices; now, the lead provinceRequire enterprises to provide shipping invoice vouchers and authorize tax audits。
In other words, if a company claims costs of 1,000 yuan, it must provide corresponding tax documentation for materials, manufacturing, sales, and logistics; failure to do so will cast doubt on the authenticity of the reported costs.
This logic has precedent cases., the unit price of valve products dropped from over RMB 300,000 in 2025 to just over RMB 100,000, a decrease of more than 50%, achieving centralized price reduction through intervention.
It is foreseeable that this governance initiative will have multifaceted impacts.In the short term, 85 products have been suspended from online listing, and enterprises that fail to reduce prices on schedule will be delisted., high-priced products are accelerating their exit from the market. In the medium term, with the rollout of the red, yellow, and green labeling system, procurement pop-up warnings at medical institutions will directly block non-selected products from entering hospitals.
In the long term, it points toward cost transparency. WhenProfits in the distribution chain are calculated precisely to the cent., companies lacking cost advantages will gradually exit the market, and the pricing logic of the consumables market will also gradually shift from enterprises to the YB side.
